Literature DB >> 27228642

Salivary Gland Ultrasonography in Sjögren's Syndrome: Clinical Usefulness and Future Perspectives.

Chiara Baldini, Nicoletta Luciano, Marta Mosca, Stefano Bombardieri.   

Abstract

In recent years, salivary gland ultrasonography (SGUS) has emerged as a promising tool for the diagnosis and prognostic stratification of patients with primary and secondary Sjögren's syndrome. Several studies have emphasized that salivary ultrasonography could be a highly specific tool for the diagnosis of the disease. However, before it can be used in daily clinical practice the SGUS procedure needs standardization and validation in larger disease-control groups. In this review we provide an update on the role of SGUS in the diagnostic algorithm of primary Sjögren's syndrome.

Entities:  

Mesh:

Year:  2016        PMID: 27228642

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  3 in total

1.  Multiple microlithiasis in bilateral parotid glands as the initial clinical manifestation of primary Sjögren's syndrome.

Authors:  Adrienn Dobai; Levente Pataky; József Barabás
Journal:  Oral Radiol       Date:  2017-06-12       Impact factor: 1.852

2.  Salivary gland ultrasonography as a predictor of clinical activity in Sjögren's syndrome.

Authors:  Tania Fidelix; Adriano Czapkowski; Sergio Azjen; Adagmar Andriolo; Virginia F M Trevisani
Journal:  PLoS One       Date:  2017-08-04       Impact factor: 3.240

3.  Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy.

Authors:  Benjamin A Fisher; Colin C Everett; John Rout; John L O'Dwyer; Paul Emery; Costantino Pitzalis; Wan-Fai Ng; Andrew Carr; Colin T Pease; Elizabeth J Price; Nurhan Sutcliffe; Jimmy Makdissi; Anwar R Tappuni; Nagui S T Gendi; Frances C Hall; Sharon P Ruddock; Catherine Fernandez; Claire T Hulme; Kevin A Davies; Christopher John Edwards; Peter C Lanyon; Robert J Moots; Euthalia Roussou; Andrea Richards; Linda D Sharples; Michele Bombardieri; Simon J Bowman
Journal:  Ann Rheum Dis       Date:  2017-12-23       Impact factor: 19.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.